[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatitis-b-virus-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatitis-b-virus-infection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,40,70,105,123,144,169,190,219],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100594837","phase-1-a-study-to-assess-the-safety-tolerability-and-pharmacokinetics-of-giga-2339-in-participants-with-chronic-hepatitis-b-virus-infection-100594837",false,"NCT07024641","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection","A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection","Key Inclusion Criteria:\n\n* Hepatitis B envelope antigen (HBeAg) negative chronic HBV infection for ≥ 6 months, defined as presence of Hepatitis B surface antigen (HBsAg) in serum for ≥ 6 months.\n* Serum HBsAg concentration between ≥ 100 international units per milliliter (IU\u002FmL) and 2000 IU\u002FmL at screening.\n* Currently on stable dose of nucleot(s)ide analogues (NAs) (≥ 6 months) and expected to continue while participating in the study, or are not received NAs.\n* Have serum HBV deoxyribonucleic acid (DNA) concentration ≤ 50 IU\u002FmL at screening (for those who are on NAs); or have serum HBV DNA concentration ≤ 2000 IU\u002FmL at screening (for those who are NOT on NAs).\n* Male participants must refrain from donating spermatozoa and agree to use highly effective contraception.\n* Female participants must not be pregnant, or breastfeeding; either should not be a woman of childbearing potential (WOCBP) or if WOCBP should use highly effective contraceptive methods.\n\nKey Exclusion Criteria:\n\n* Positive for co-infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), and\u002For hepatitis D virus (HDV) at screening.\n* Participants that weigh less than 50 kilograms (kg) and\u002For have a body mass index (BMI) less than 18.5.\n* History of documented liver cirrhosis at screening. Patients under liver cirrhosis evaluation at screening will not be eligible until cirrhosis is ruled out.\n* Liver stiffness \\> 8 kilopascal (kPa) at screening.\n* History of chronic liver disease from another cause, immune complex disease, or autoimmune diseases that in the opinion of the investigator would preclude participation.\n* Family history of hepatocellular carcinoma (HCC).\n* Alpha fetoprotein \\> 20 nanograms per milliliter (ng\u002FmL).\n* Presence of a liver imaging reporting and data system (LI-RADS) 4 or 5 liver lesion on imaging 12 months prior to Screening OR, LI-RADS-US findings of US-3 grade on imaging 12 months prior to Screening, OR LIRADS-US grade 3 done prior to the D1 infusion visit, if prior LI-RADS or LI-RADS-US results are not available at Screening.\n* History of hematopoietic stem cell transplant or solid organ transplant.\n* Receipt of anti-HBV monoclonal antibody (mAb)\u002FpAb therapy of any kind in the past (including hepatitis B immunoglobulin \\[HBIG\\]).\n* History of cardiovascular disease (e.g., coronary artery disease, cardiomyopathy, congestive heart failure, family history of congenital long QT syndrome). Stable hypertension is allowed.\n* Malignancy diagnosed and\u002For treated within 5 years prior to Screening, and\u002For with ongoing treatment for malignancy, with the exception of localized non-metastatic basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix excised with curative intent.\n* Participants requiring anti-coagulation therapies (for example warfarin, Factor Xa inhibitors, or anti-platelet agents like clopidogrel).\n* Male participants with a corrected QT interval using Fridericia's formula (QTcF) \\> 450 milliseconds (msec) and female participants with QTcF \\> 470 msec on ECG recorded at screening. if the participant has evidence of an intraventricular conduction delay, defined as QRS interval greater than 110 msec, a QTcF is \\> 500 msec for both males and females will be excluded.\n* Known hypersensitivity to any GIGA-2339 excipients or any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (nonactive hay fever is acceptable), or a history of drug or other allergy that, in the opinion of the Investigator, contraindicates participation.\n* Received or will receive live-attenuated virus vaccinations such as measles, mumps, rubella or varicella within 4 weeks before and up to three months after administration of investigational product (IP).","ALL","18 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.",[26],"Hepatitis B Virus Infection","RECRUITING","2026-06-23",{"date":30,"type":31},"2026-06-25","ACTUAL",{"date":33,"type":31},"2024-11-13",{"date":35,"type":20},"2028-11",{"name":37,"class":38},"GigaGen, Inc.","INDUSTRY",18,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100611420","the-role-and-regulatory-mechanism-of-germinal-center-immune-response-in-hepatitis-b-virus-infection-100611420","NCT07240350","The Role and Regulatory Mechanism of Germinal Center Immune Response in Hepatitis B Virus Infection","Inclusion Criteria:\n\n1. Male or female, patients with chronic hepatitis B and hepatitis B surface antigen negative patients with clinical diagnosis who need to undergo liver, spleen, tonsil or lymph node surgery.\n2. Before performing any research-related steps, the patient understood the research process, signed the informed consent, and complied with the research requirements.\n3. Patients diagnosed with chronic hepatitis B virus infection according to the \"Guidelines for the Prevention and Treatment of Chronic Hepatitis B(2019 Version)\" .\n\nExclusion Criteria:\n\n1. Those concomitant HCV, HIV infection, alcoholic fatty liver disease, non-alcoholic fatty liver disease, and autoimmune liver disease , etc. were excluded.\n2. Diseases of the immune system or coagulation system, such as hyperthyroidism, diabetes, thrombocytopenic purpura, etc., were excluded.\n3. Exclude serious underlying diseases that affect the immune status of the body.\n4. The investigator believes that there are other circumstances that are not suitable for inclusion.",true,"75 Years",{"count":49,"type":20},280,"3 Years","OBSERVATIONAL","The purpose of this observational study is to investigate the structure and composition of germinal centers in individuals with chronic HBV infection. The primary questions it aims to address are:\n\nWhat are the phenotypes, functions, and complexity of B cell clones of the immune cells within the germinal centers of chronic HBV-infected individuals? Do chronic HBV-infected individuals have ectopic germinal centers in the liver? This will be studied by collecting peripheral blood and discarded liver, lymph node, and tonsil tissues from chronic HBV patients undergoing lymph node surgery, hepatectomy, and tonsillectomy.",[26],[55,56,57,58],"Germinal center","humoral immunity","immune response","hepatitis B virus infection","2026-04-13",{"date":61,"type":31},"2026-04-16",{"date":63,"type":31},"2021-01-01",{"date":65,"type":20},"2027-02-12",{"name":67,"class":68},"Nanfang Hospital, Southern Medical University","OTHER",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100619514","phase-4-entecavir-with-or-without-pegylated-interferon--2b-in-children-aged-3-6-years-with-immune-active-chronic-hepatitis-b-100619514","NCT07345611","Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B","Efficacy and Safety of Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3 to 6 Years With Chronic Hepatitis B in the Immune-Clearance Phase (B-Young-Cure-2): A Multicenter, Open-Label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age between 3 and 6 (more than 3 but less than 7) years;\n2. Chronic HBV infection;\n3. Positive HBeAg;\n4. HBV DNA \\>1.0×10⁴ IU\u002FmL;\n5. Normal upper abdominal ultrasound without cirrhosis or hepatocellular carcinoma;\n6. ALT \\>40 U\u002FL.\n\nExclusion Criteria:\n\n1. Previous antiviral treatment for chronic HBV infection;\n2. Coinfection with hepatitis C, D, E, human immunodeficiency virus (HIV), Epstein-Barr virus, or cytomegalovirus;\n3. Previous or current evidence of hepatocellular carcinoma or cirrhosis;\n4. Coexistence of any other liver diseases such as autoimmune hepatitis, drug-induced liver injury or Wilson's disease;\n5. Coexistence of systemic\u002Fother organ disorders (for example with evidence of thyroid disorders);\n6. Hemoglobin level \\\u003C100 g\u002FL;\n7. Absolute neutrophil count \\\u003C1.0×10⁹\u002FL.;\n8. Platelet count \\\u003C125×10⁹\u002FL;\n9. Total bilirubin \\>1 ULN, i.e., 17.1 μmol\u002FL;\n10. Albumin level \\\u003C35 g\u002FL;\n11. Concurrent treatment with other drugs, including but not limited to nephrotoxic drugs, immune modulators, cytotoxic drugs, Chinese traditional medicine or supplements, nonsteroidal anti-inflammatory drugs, or steroids.","6 Years",{"count":79,"type":20},60,[81],"PHASE4","This study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-active, HBeAg-positive children aged 3-6 years with chronic hepatitis B.",[26,84,85],"Children","Chronic Hepatitis B",[84,87,88,89,90,91,92,93,94],"Efficacy","Immune clearance","Safety","Chronic","Entecavir","Pegylated interferon α-2b","Functional cure","Hepatitis B virus","NOT_YET_RECRUITING","2026-01-07",{"date":98,"type":31},"2026-01-16",{"date":100,"type":20},"2026-01-11",{"date":102,"type":20},"2030-12-31",{"name":104,"class":68},"Qing-Lei Zeng",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":77,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":121,"leadSponsor":122,"locationsCount":4},"100619515","phase-4-entecavir-with-or-without-pegylated-interferon--2b-in-children-aged-3-6-years-with-immune-tolerant-chronic-hepatitis-b-100619515","NCT07345624","Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B","Efficacy and Safety of Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3 to 6 Years With Immune-Tolerant Chronic Hepatitis B Virus Infection (B-Young-Cure-1): A Multicenter, Open-Label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 3-6 (more than 3 but less than 7) years;\n2. With chronic HBV infection;\n3. HBeAg-positive;\n4. HBV DNA \\>1.0×10⁷ IU\u002FmL;\n5. Normal upper abdominal ultrasound;\n6. ALT \\\u003C40 U\u002FL, HBsAg positivity, HBeAg positivity, and HBV DNA\\>1.0×10⁷IU\u002FmL for at least two times, with an interval of 6 months or more.\n\nExclusion Criteria:\n\n1. Previous antiviral treatment for chronic HBV infection;\n2. Coinfection with hepatitis C, D, E, human immunodeficiency virus (HIV), Epstein-Barr virus, or cytomegalovirus;\n3. Previous or current evidence of hepatocellular carcinoma or cirrhosis;\n4. Coexistence of any other liver diseases such as autoimmune hepatitis, drug-induced liver injury or Wilson's disease;\n5. Coexistence of systemic\u002Fother organ disorders (for example with evidence of thyroid disorders);\n6. Hemoglobin level \\\u003C100 g\u002FL.\n7. Absolute neutrophil count \\\u003C1.0×10⁹\u002FL;\n8. Platelet count \\\u003C125×10⁹\u002FL;\n9. Total bilirubin \\>1 ULN, i.e., 17.1 μmol\u002FL;\n10. Albumin level \\\u003C35 g\u002FL;\n11. Concurrent treatment with other drugs, including but not limited to nephrotoxic drugs, immune modulators, cytotoxic drugs, Chinese traditional medicine or supplements, nonsteroidal anti-inflammatory drugs, or steroids.",{"count":113,"type":20},80,[81],"This study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-tolerant, HBeAg-positive children aged 3-6 years with chronic hepatitis B virus infection.",[26,84,85],[84,87,89,90,92,94,91,93,118],"Immune-tolerant",{"date":98,"type":31},{"date":100,"type":20},{"date":102,"type":20},{"name":104,"class":68},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":46,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":69},"100612797","phase-4-strengthening-hepatitis-b-screening-linkage-to-care-and-long-term-monitoring-in-phichit-province-thailand-a-birth-bohort-approach-100612797","NCT07258251","Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach","HBV-PHICHIT","Inclusion Criteria:\n\n* Adults born before January 1, 1992\n* Residing in Phichit Province\n* Individuals who test positive for HBsAg will be invited to participate in the follow-up cohort\n* HBsAg positive patients who are already under care will also be invited to participate\n\nExclusion Criteria:\n\n* Subjects who withdraw consent",{"count":131,"type":20},6000,[81],"This study in Phichit province, Thailand, aims to find and support adults born before 1992 who are at high risk for hepatitis B infection. Many people in this group were born before the universal hepatitis B vaccine was available and may not know they are infected. The study will invite nearly 240,000 eligible adults for free hepatitis B screening. Those who test positive will be linked to care at one of 12 district hospitals. Doctors will use simplified 2024 World Health Organization (WHO) guidelines to decide who needs treatment. Eligible individuals will receive a safe, effective daily medicine (tenofovir alafenamide). The study will use community health volunteers and phone reminders to help patients stay in care and take their medication regularly. Over three years, the study will track improvements in liver health and virus levels, aiming to prevent liver cirrhosis and cancer.",[85,26],"2025-11-20",{"date":137,"type":31},"2025-12-02",{"date":139,"type":20},"2026-01-01",{"date":141,"type":20},"2028-12-31",{"name":143,"class":68},"The Task Force for Global Health",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":151,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":21,"phases":154,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":69},"100584372","phase-3-optimal-timing-of-hepatitis-b-vaccination-after-transplants-100584372","NCT06888479","Optimal Timing of Hepatitis B Vaccination After Transplants","Optimal Timing of Hepatitis B Vaccination After Transplants: a Randomized Clinical Study","Inclusion Criteria:\n\n1. Patients must be ≥ 16 years old;\n2. Patients receiving hematopoietic cell transplantation;\n3. Patients achieving complete molecular remission;\n4. Patients or their guardians have to sign an informed consent form before the start of the research procedure.\n\nExclusion Criteria:\n\n1. Multiple transplantations;\n2. Donors' HBV-DNA or HBsAg are positive;\n3. Patients' HBV-DNA or HBsAg are positive before transplantation or \\\u003C 3 months after transplantation;\n4. Patients who are unable to comply with the research treatments and monitoring requirements due to mental or other medical conditions;\n5. Patients who are ineligible for the study due to other reasons which would cause unacceptable risks to the patients.","16 Years",{"count":153,"type":20},1500,[155],"PHASE3","The investigators aim to perform a randomized clinical trial to determine the optimal timing of hepatitis B vaccination after hematopoietic cell transplantation (HCT) through evaluating the immunity effect of two different vaccination schedules (initiated at 3 or 6 months after transplantation) in patients with different immune reconstitution status.",[158,26,159],"Transplant-Related Disorder","Vaccine Reaction","2025-03-20",{"date":162,"type":31},"2025-03-21",{"date":164,"type":20},"2025-06-01",{"date":166,"type":20},"2029-03-01",{"name":168,"class":68},"Institute of Hematology & Blood Diseases Hospital, China",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":178,"studyType":51,"phases":4,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":69},"100443184","a-non-interventional-registry-for-patients-with-hepatitis-b-virus-infection-100443184","NCT05051098","A Non-interventional Registry for Patients with Hepatitis B Virus Infection","The European HBV Registry: a Joint Initiative of TherVacB and DZIF","Inclusion Criteria:\n\n* Hepatitis B Virus Infection\n\nTherVacB sub-cohort:\n\n* confirmed chronic hepatitis B virus infection: HBsAg positive for at least 1 year prior inclusion\n* HBeAg status documented for at least 6 months\n\nExclusion Criteria:\n\nTherVacB sub-cohort:\n\n* age \\>70 years\n* co-infection with HIV, HCV (RNA positive),\n* clinically relevant concomitant liver diseases (ALD, NASH, Haemochromatosis, Autoimmune hepatitis, AT1, Wilson's disease, primary biliary cirrhosis etc.)\n* significant comorbidities (e.g. malignancies)\n* immunosuppressive treatment (\\> 40 mg Cortisol- equivalent)\n* liver cirrhosis (judged clinically or based on ultrasound\u002Ftransient elastography)\n* History of hepatocellular carcinoma",{"count":177,"type":20},3000,"5 Years","In order to tackle the unmet needs in chronic HBV infection, a consortium of clinical partners has gathered to establish a registry for patients with hepatitis B mono- and co-infections. The partners will build up a European-wide registry to be able to stratify patients for upcoming clinical trials.\n\nExtensive analyses of virus and host-specific parameters are to be carried out from these patients. The knowledge gained thereby should contribute to a better understanding of the HBV control and enable patient stratification with regard to immunomodulatory therapies.\n\nFurthermore, hepatitis B patients are to be identified who are willing to participate in future studies to investigate immunotherapies to cure HBV infections (e.g. therapeutic vaccines).",[26],"2025-03-11",{"date":183,"type":31},"2025-03-13",{"date":185,"type":31},"2021-05-06",{"date":187,"type":20},"2025-12",{"name":189,"class":68},"Hannover Medical School",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":46,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":197,"targetDuration":199,"studyType":51,"phases":4,"briefSummary":200,"conditions":201,"keywords":206,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":69},"100517862","hepatitis-b-vaccination-after-neonatal-surgery-100517862","NCT06023056","Hepatitis B Vaccination After Neonatal Surgery","Influence of Delayed Vaccination of Hepatitis B Vaccine on Vaccination Safety and Immune Response of Newborns After Gastrointestinal Surgery","Inclusion Criteria:\n\n1\\. Term neonates; 2. Underwent staged gastrointestinal surgery; 3. HBsAg-; 4. No immune system disease; 5.no serious defect of heart, brain, liver, kidney and other organs.\n\nExclusion Criteria:\n\n1\\. Premature; 2. HBsAg+; 3. Having immune system diseases; 4. Having serious defect of heart, brain, liver, kidney and other organs; 5. Lost patients.",{"count":198,"type":20},180,"2 Years","At present, whether the hepatitis B vaccine (HBV) can be vaccinated on time after neonatal surgery has become a common problem for children's families, neonatal surgeons, and vaccination departments, but there are few relevant studies at home and abroad, and there is no corresponding guide or consensus. In the early stage, our research team investigated the vaccination plans of the vaccination units in the main urban areas of Chongqing for such children through telephone follow-up, and found that the practices of each unit were different, all based on their own experience, and there was no clear evidence to support the vaccination or should not be vaccinated, which may cause some children to miss the best vaccination time or increase the risk of vaccination. The center is a relatively large neonatal surgery center in southwest China. The diagnosis and treatment of neonatal digestive tract malformations is at the leading level in China. It can carry out various neonatal operations such as neonatal necrotizing enterocolitis, congenital anorectal malformations, and congenital megacolon. On average, it carries out more than 30 third and fourth grade neonatal gastrointestinal operations every month. It has accumulated a lot of experience in the follow-up of newborns, There is a large amount of clinical data support for children who need to be vaccinated after surgery, so it is planned to follow up the second and third doses of hepatitis B vaccine and whether there are adverse reactions related to vaccination for children who need to be vaccinated after gastrointestinal surgery in the neonatal period, and at the same time check the production of HBsAb after vaccination, The immune response and adverse reactions of hepatitis B vaccine at different time points after surgery were studied to increase clinical evidence for the determination of hepatitis B vaccine vaccination program for newborns after surgery.",[202,26,203,204,205],"Vaccination Reaction","Digestive System Disorders of Fetus and Newborn","Blood Transfusion Complication","Hepatitis B Vaccine Adverse Reaction",[207,205,208,209],"Hepatitis B Vaccination Reaction","Neonatal surgery","Gastrointestinal Surgery","2023-09-07",{"date":212,"type":31},"2023-09-11",{"date":214,"type":31},"2022-11-01",{"date":216,"type":20},"2030-11-01",{"name":218,"class":68},"Children's Hospital of Chongqing Medical University",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":46,"sex":16,"minAge":17,"maxAge":226,"enrollmentInfo":227,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":229,"conditions":230,"keywords":231,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":69},"100469405","treatment-and-prognosis-of-patients-with-chronic-hbv-infection-100469405","NCT05392387","Treatment and Prognosis of Patients With Chronic HBV Infection","Study on the Antiviral Therapy and Prognosis of Patients With Chronic HBV Infection","Inclusion Criteria:\n\npatients with evidence of chronic HBV infection\n\nExclusion Criteria:\n\nchronic liver injury mainly caused by other reasons, such as autoimmune diseases, alcohol, drugs and so on.","79 Years",{"count":228,"type":20},500,"Hepatitis B virus (HBV) infection is a major global health issue with 257 million chronically infected individuals. Of note, China has the largest population accounting for one third of the world's infected population. Approximately, about 300 000 people die each year due to the consequences of HBV. In 2016, the World Health Organization (WHO) proposed the goal for elimination of hepatitis B as public health threat by 2030 and China will be a major contributor towards this global goal. Currently, two approved therapeutic strategies are available including pegylated interferon (IFN) or nucleos (t) ide analogues (NA), which could suppress HBV replication and slow disease progression. Here, investigators hope to launch a cohort study to reveal the clinical features relating to therapeutic efficacy of antiviral therapy and the prognosis of patients with differential therapeutic strategies.",[26],[26,232,233],"antiviral therapy","prognosis","2022-05-22",{"date":236,"type":31},"2022-05-26",{"date":238,"type":31},"2021-10-25",{"date":240,"type":20},"2026-10-25",{"name":242,"class":68},"Xiangya Hospital of Central South University"]